Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

The mean of qPCR Ct values (P < 0.001) and 25-hydroxy vitamin D (P < 0.001) in the Delta variant was lower than other variants.Comparison of laboratory parameters between SARS-CoV-2 variants.VariablesSARS-CoV-2 variantsP-valueAlpha (n = 1395)Delta (n = 1425)Omicron BA.5 (n = 1510)Deceased/recovered patients632/763 (45.3/54.7%)913/512 (64.1/35.9%)478/1032 (31.7/68.3%) < 0.001*Mean age ± SD54.7 ± 12.557.3 ± 12.152.4 ± 13.1 < 0.001*Gender (male/female)735/660 (52.7/47.3%)760/665 (53.3/46.7%)765/745 (50.7/49.3%)0.317ALT, IU/L (mean ± SD) (Reference range: 5 to 40)38.1 ± 24.740.1 ± 24.636.9 ± 24.7 < 0.001*AST, IU/L (mean ± SD) (Reference range: 5 to 40)33.2 ± 14.434.7 ± 14.034.4 ± 16.20.002*ALP, IU/L (mean ± SD) (Reference range: up to 306)184.5 ± 80.8188.8 ± 76.5186.0 ± 87.50.130Cholesterol, mg/dL (mean ± SD) (Reference range: 50 to 200)120.8 ± 39.1120.6 ± 39.7115.8 ± 33.10.007*TG, mg/dL (mean ± SD) (Reference range: 60 to 165)125.0 ± 53.0120.7 ± 48.8127.8 ± 58.10.084LDL, mg/dL (mean ± SD) (Reference range: up to 150)96.0 ± 48.384.1 ± 44.588.3 ± 47.6 < 0.001*HDL, mg/dL (mean ± SD) (Reference range: > 40)32.8 ± 11.632.0 ± 11.433.0 ± 11.40.016*WBC, 109/L (mean ± SD) (Reference range: 4000 to 10,000)7645.4 ± 2786.57607.0 ± 2704.97685.1 ± 2931.20.922CRP, mg/L (mean ± SD) (Reference range: < 10 mg/L Negative)61.2 ± 22.064.3 ± 21.760.1 ± 21.2 < 0.001*ESR, mm/1st h (mean ± SD) (Reference range: 0 to 15)50.2 ± 16.252.7 ± 16.149.2 ± 15.7 < 0.001*FBS, mg/dL (mean ± SD) (Reference range: 70 to 100)108.0 ± 41.6108.8 ± 42.5106.1 ± 41.00.024*Platelets × 1000/cumm (mean ± SD) (Reference range: 140,000 to 400,000)184 ± 71184 ± 74184 ± 700.800Uric acid, mg/dL (mean ± SD) (Reference range: 3.6 to 6.8)4.8 ± 1.84.4 ± 1.75.1 ± 1.8 < 0.001*Creatinine, mg/dL (mean ± SD) (Reference range: 0.6 to 1.4)0.9 ± 0.31.0 ± 0.30.9 ± 0.3 < 0.001*qPCR Ct value20.2 ± 6.417.7 ± 6.221.2 ± 6.2 < 0.001*25-hydroxy vitamin D, ng/mL (mean ± SD) (Sufficiency: 21 to 150)31.8 ± 12.829.7 ± 12.333.6 ± 13.2 < 0.001*CRP rs1205 < 0.001*CC389 (27.9%)409 (28.7%)630 (41.7%)CT784 (56.2%)723 (50.7%)659 (43.7%)TT222 (15.9%)293 (20.6%)221 (14.6%)CRP rs1800947 < 0.001*CC274 (19.6%)291 (20.4%)328 (21.7%)CG937 (67.2%)889 (62.4%)1011 (66.5%)GG184 (13.2%)245 (17.2%)171 (11.8%)ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; TG, triglyceride; LDL, low density lipoprotein; HDL, high density lipoprotein; WBC, white blood cells; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; FBS, fasting blood glucose; SD, standard deviation; SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2. *Statistically significant (< 0.05).

Source: The demographic properties of COVID-19 patients. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Out of 13,450 cases, 4330 patients were recruited based on inclusion criteria, which include Kurdish nationality along with the same ethnicity, patients without prior infections with COVID-19 and vaccinations against SARS-CoV-2, and the absence of underlying comorbidities, including heart, lung, kidney, liver, cancer, autoimmune disease, diabetes, pregnancy, immunocompromised diseases, obesity, and diabetes.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

The death rate of COVID-19 infection in different SARS-CoV-2 variants was related to C-reactive protein gene polymorphisms

Study design awaiting verification · Scientific Reports · 2024

Original publication title

The death rate of COVID-19 infection in different SARS-CoV-2 variants was related to C-reactive protein gene polymorphisms

Sahar Sadeghi Mofrad; Shayan Boozarjomehri Amnieh; Mohammad Reza Pakzad; Mina Zardadi; Morteza Ghazanfari Jajin; Enayat Anvari; Sina Moghaddam; Abolfazl Fateh

© The Author(s) 2024

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

The serum level of C-reactive protein (CRP) is a significant independent risk factor for Coronavirus disease 2019 (COVID-19). A link was found between serum CRP and genetic diversity within the CRP gene in earlier research. This study examined whether CRP rs1205 and rs1800947 polymorphisms were associated with COVID-19 mortality among various severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) variants. We genotyped CRP rs1205 and rs1800947 polymorphisms in 2023 deceased and 2307 recovered patients using the polymerase chain reaction-restriction fragment length polymorphism method.

There was a significant difference between the recovered and the deceased patients in terms of the minor allele frequency of CRP rs1205 T and rs1800947 G. In all three variants, COVID-19 mortality rates were associated with CRP rs1800947 GG genotype. Furthermore, CRP rs1205 CC and rs1800947 GG genotypes showed higher CRP levels. It was found that the G-T haplotype was prevalent in all SARS-CoV-2 variants. The C: C and C: T haplotypes were statistically significant in Delta and Omicron BA.5 variants, respectively.

In conclusion, polymorphisms within the CRP gene may relate to serum CRP levels and mortality among COVID-19 patients. In order to verify the utility of CRP polymorphism correlation in predicting COVID-19 mortality, a replication of these results is needed.

Authors’ abstract

The serum level of C-reactive protein (CRP) is a significant independent risk factor for Coronavirus disease 2019 (COVID-19). A link was found between serum CRP and genetic diversity within the CRP gene in earlier research. This study examined whether CRP rs1205 and rs1800947 polymorphisms were associated with COVID-19 mortality among various severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) variants. We genotyped CRP rs1205 and rs1800947 polymorphisms in 2023 deceased and 2307 recovered patients using the polymerase chain reaction-restriction fragment length polymorphism method.

There was a significant difference between the recovered and the deceased patients in terms of the minor allele frequency of CRP rs1205 T and rs1800947 G. In all three variants, COVID-19 mortality rates were associated with CRP rs1800947 GG genotype. Furthermore, CRP rs1205 CC and rs1800947 GG genotypes showed higher CRP levels. It was found that the G-T haplotype was prevalent in all SARS-CoV-2 variants. The C: C and C: T haplotypes were statistically significant in Delta and Omicron BA.5 variants, respectively.

In conclusion, polymorphisms within the CRP gene may relate to serum CRP levels and mortality among COVID-19 patients. In order to verify the utility of CRP polymorphism correlation in predicting COVID-19 mortality, a replication of these results is needed.

Publication and source details

Original title: The death rate of COVID-19 infection in different SARS-CoV-2 variants was related to C-reactive protein gene polymorphisms

Sahar Sadeghi Mofrad; Shayan Boozarjomehri Amnieh; Mohammad Reza Pakzad; Mina Zardadi; Morteza Ghazanfari Jajin; Enayat Anvari; Sina Moghaddam; Abolfazl Fateh

Scientific Reports · 2024

© The Author(s) 2024https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T13:40:59.372183+00:00

DOI: 10.1038/s41598-024-51422-y · PMC10771501